Assembly Biosciences, Inc.

ASMB ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-42.8M $-44.3M $-28.5M $-23.8M $-19.4M $-24.8M $-34.3M $-15.3M
Depreciation & Amortization $219.0K
Depreciation $200.0K $80.0K $65.0K $11.0K $6.2K $4.6K $3.7K $12.5K
Amortization
Stock-Based Compensation $8.6M $5.0M $7.9M $10.6M $1.7M $2.8M $3.0M $2.4M
Net Cash from Operating Activities $1.9M $-34.9M $-18.7M $-15.0M $-17.8M $-21.4M $-25.1M $-5.2M
Investing Activities
Capital Expenditures $865.0K $147.0K $58.3K $150.0K $6.5K $3.2K $12.0K $0
Business Acquisitions $0 $0 $-509.4K $0
Net Cash from Investing Activities $-15.6M $36.2M $-64.9M $277.4K $-6.5K $-3.2K $-12.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $67.2M $153.0K $81.6M $16.7M $24.4M $4.9M $47.5M $19.7M
Net Change in Cash $53.5M $1.5M $-2.0M $2.0M $6.6M $-16.5M $22.4M $14.5M
Free Cash Flow $995.0K $-35.0M $-18.8M $-15.1M $-17.8M $-21.4M $-25.1M $-5.2M
← Newer Page 2 of 3 Older →